Retrospective Cohort Study
Copyright ©The Author(s) 2016.
World J Hepatol. May 8, 2016; 8(13): 597-604
Published online May 8, 2016. doi: 10.4254/wjh.v8.i13.597
Table 1 Patient characteristics (n = 123) at the start of the follow-up period
Gender (male/female) 71/52
Age (yr) 69.7 ± 8.0
Hepatitis (HBV/HCV) 12/111
CP score (5/6/7/8) 79/22/15/7
CP class (A/B/C) 102/21/0
Size of tumor (mm) 20.6 ± 7.7
No. of tumor(s) (1/2/3/4) 78/30/13/2
Total bilirubin (mg/dL) 0.97 ± 0.4
Albumin (g/dL) 3.7 ± 0.6
Prothrombin time (%) 90.5 ± 15
Platelet count (104/μL) 11.1 ± 5.0
AST (IU/L) 58.2 ± 32.1
ALT (IU/L) 53.0 ± 39.7
Hepatitis condition RVH group/CAH group 13/110
Prior TACE with TACE/without TACE 110/13
HBV: Hepatitis B virus; CP: Child-Pugh; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; RVH: Remission status of viral hepatitis; CAH: Chronic active hepatitis; HCV: Hepatitis C virus; TACE: Transarterial chemoembolization.